University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...
An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...
The US regulatory agency has pushed the PDUFA date by three months to 18 March 2025 to “allow for more time to review ...
Several years of preliminary research results suggest chimeric antigen receptor (CAR) T-cell therapy could benefit pediatric patients with refractory systemic lupus erythematosus (SLE). The gene ...
In this GEN webinar, our speakers will present important considerations for quality control testing for biosafety and product ...
BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...
On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON ...
The global cell and gene therapy market size was valued at USD 30.27 billion in 2024 and is projected to reach USD 190.82 ...
To improve long-term persistence and reduce the risk of immune rejection, researchers are exploring ways to diminish the ...
Its lead gene therapy candidate has the potential to be faster, less expensive, and more widely available than current CAR T ...
University of Wisconsin-Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...